Treatment of persistent ventricular tachycardia: Drugs or ablation?

• Published in: Trends in cardiovascular medicine Vol. 27; no. 7; pp. 506 - 513
• Main Authors: MacIntyre, Ciorsti J., MD, FRCPC, Sapp, John L., MD, FRCPC, FHRS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2017; Elsevier Limited
• Subjects: Anti-Arrhythmia Agents - adverse effects; Anti-Arrhythmia Agents - therapeutic use; Antiarrhythmics; Arrhythmia; Cardiac arrhythmia; Cardiovascular; Cardiovascular disease; Catheter Ablation - adverse effects; Catheters; Defibrillators; Defibrillators, Implantable; Electric Countershock - instrumentation; Humans; Mortality; Patient Selection; Recurrence; Risk Assessment; Risk Factors; Tachycardia; Tachycardia, Ventricular - diagnosis; Tachycardia, Ventricular - mortality; Tachycardia, Ventricular - physiopathology; Tachycardia, Ventricular - therapy; Treatment Outcome; Ventricle
• ISSN: 1050-1738; 1873-2615
• DOI: 10.1016/j.tcm.2017.05.004

Abstract Implantable cardioverter defibrillators (ICDs) reduce the mortality risk associated with recurrent ventricular tachycardia (VT) and can frequently terminate VT episodes painlessly, but do not prevent recurrent episodes. For patients with symptomatic recurrences, frequent asymptomatic recurrences, ICD shocks, or VT storm, most clinicians recommend strategies to suppress VT. The proarrhythmic mortality risk of antiarrhythmic drugs (AADs) may be mitigated by the presence of an ICD, but these medications are limited by high recurrence rates, and unfavorable side effect profiles. Catheter ablation is an alternative or adjunctive option, but is also limited by incomplete efficacy and procedural risk.